TFEB has been reported to enhance PD‐L1 expression in RCC cells, thus mediating resistance to mTOR inhibition.[48] IFN‐γ, secreted by activated T cells and NK cells, stimulates tumor cells to overexpress PD‐L1 through the JAK‐STAT pathway.[49] During tumor progression, IFN‐γ‐derived PD‐L1 promotes tumor immune evasion. The gene discussed is CD274; the disease is neoplasm.